Evidence mapPaperPMID 37345424Full record

ReviewExpert reviews in molecular medicine2023

Toxicology of pharmaceutical and nutritional longevity compounds.

Cigdem Kahraman, Duygu Kaya Bilecenoglu, Suna Sabuncuoglu, Irem Tatli Cankaya

Abstract readReview
In one paragraph

Review in Expert reviews in molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cigdem KahramanDepartment of Pharmacognosy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey.ORCID 0000-0001-8096-0738
Duygu Kaya BilecenogluFaculty of Health Sciences, Aydın Adnan Menderes University, Aydın, Turkey.ORCID 0000-0003-3483-1518
Suna SabuncuogluDepartment of Pharmaceutical Toxicology, Hacettepe University Faculty of Pharmacy, Ankara, Turkey.ORCID 0000-0002-9702-4214
Irem Tatli CankayaDepartment of Pharmaceutical Botany, Hacettepe University Faculty of Pharmacy, Ankara, Turkey.ORCID 0000-0001-8531-9130

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aging is the most prominent risk factor for many diseases, which is considered to be a complicated biological process. The rate of aging depends on the effectiveness of important mechanisms such as the protection of DNA from free radicals, which protects the structural and functional integrity of cells and tissues. In any organism, not all organs may age at the same rate. Slowing down primary aging and reaching maximum lifespan is the most basic necessity. In this process, it may be possible to slow down or stabilise some diseases by using the compounds for both dietary and pharmacological purposes. Natural compounds with antioxidant and anti-inflammatory effects, mostly plant-based nutraceuticals, are preferred in the treatment of age-related chronic diseases and can also be used for other diseases. An increasing number of long-term studies on synthetic and natural compounds aim to elucidate preclinically and clinically the mechanisms underlying being healthy and prolongation of life. To delay age-related diseases and prolong the lifespan, it is necessary to take these compounds with diet or pharmaceuticals, along with detailed toxicological results. In this review, the most promising and utilised compounds will be highlighted and it will be discussed whether they have toxic effects in short/long-term use, although they are thought to be used safely.

Indexed as

LongevityPharmacyAgingHumansPharmaceutical PreparationsRisk FactorsPharmaceutical PreparationsAnti-aging compoundsastaxanthincaffeinecurcuminfucoxanthinmetforminrapamycinresveratrolspermidineα-lipoic acid

Identifiers

PMID37345424
PMCPMC10752229

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.